Jaguar Health Files 8-K: Material Agreement, Equity Sales

Ticker: JAGX · Form: 8-K · Filed: May 22, 2025 · CIK: 1585608

Sentiment: neutral

Topics: material-agreement, equity-sale, regulation-fd

TL;DR

Jaguar Health signed a big deal and sold some stock.

AI Summary

On May 20, 2025, Jaguar Health, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity for Jaguar Health, including a new material agreement and equity transactions, which could impact its financial standing and stock performance.

Risk Assessment

Risk Level: medium — The filing details material agreements and unregistered equity sales, which can introduce financial and regulatory risks.

Key Players & Entities

FAQ

What type of material definitive agreement did Jaguar Health, Inc. enter into?

The filing states that Jaguar Health, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in this summary.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on May 20, 2025.

What is Jaguar Health, Inc.'s state of incorporation?

Jaguar Health, Inc. is incorporated in Delaware.

What is the SEC file number for Jaguar Health, Inc.?

The SEC file number for Jaguar Health, Inc. is 001-36714.

What is the address of Jaguar Health, Inc.'s principal executive offices?

The principal executive offices of Jaguar Health, Inc. are located at 200 Pine Street, Suite 400, San Francisco, California 94104.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 22, 2025 regarding Jaguar Health, Inc. (JAGX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing